Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
161
resultados
Última actualización
05/04/2026 [06:53:00]
Resultados 75 a 100 de 161
Resumen de: CN121736299A
本发明公开了一种钾离子响应型可聚集金纳米粒及其制备方法,该可聚集金纳米粒由钾离子识别型共聚物接枝在金纳米颗粒表面，所述共聚物的结构式如下：其中，x/(x+y+z)＝0.1～0.3，y/(x+y+z)＝0.1～0.3，z/(x+y+z)＝0.4～0.8，x+y+z＝10～300。该可聚集金纳米粒由钾离子识别型共聚物加入去离子水溶解后，与柠檬酸钠还原法制备的单分散性良好的金纳米颗粒在氮气保护下常温共孵育即得。本发明中的聚合物在识别肿瘤微环境中异常钾离子浓度后由亲水性转为疏水性，金纳米颗粒发生团聚，同时呈现出增强的光声信号及光热效应。制备方法简单，生物相容性良好,可用于不同类别肿瘤治疗。
Resumen de: CN121731244A
本发明涉及基因工程药物和疫苗制造领域，特别涉及到一种核酸‑小分子药物共递送系统及其制备方法和应用。本发明所述的核酸‑小分子药物共递送系统以脂质组分为载体，所述载体对药物组分进行包封，所述脂质组分包括阳离子脂质、中性磷脂、胆固醇和PEG‑脂质；所述药物组分包括核酸药物和小分子药物；所述核酸‑小分子药物共递送系统的粒径为50‑300 nm。经实验验证，本申请公开的核酸‑小分子药物共递送系统，在抗炎、免疫调节和抗肿瘤领域具有广阔的应用前景。
Resumen de: CN120570996A
The invention discloses a novel application of emodin and a high-density lipoprotein analogue in preparation of a medicine for treating brain nerve injury, and the high-density lipoprotein analogue comprises apolipoprotein A-1 single mimetic peptide and natural phospholipid. The invention has the advantages of long-term stability and no immunogenicity and organ toxicity risk, thereby providing a clinically convertible solution for precise treatment of nerve injury.
Resumen de: AU2024312860A1
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.
Resumen de: AU2024307699A1
Disclosed herein is a bioactive polymer for forming a solution and/or hydrogel to stabilise one or more pharmaceutically active agents prior to, during or post-administration, the polymer comprising a first monomer for binding water, a second monomer for imparting mechanical properties to the scaffold; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting phase-transition behaviour. Preferably, the first monomer is OEGMA; the second monomer is PLA/HEMA; the third monomer is NAS; and the fourth monomer is NIPAAm, and the polymer comprises: OEGMA in an amount of from about 1 to about 15 mol%; PLA/HEMA in an amount of from 5 to about 50 mol%; NAS in an amount of from 0 to about 15 mol%; and NIPAAm in an amount of up to about 85 mol%.
Resumen de: CN121737085A
本公开提供了一种新的核酸酶和使用该核酸酶进行基因编辑和核酸检测的方法。在一些实施方案中，本公开提供了该可编程核酸酶是的应用。本公开还提供了包含该可编程核酸酶的组合物、系统和方法。
Resumen de: WO2025045142A1
Disclosed herein are immunogenic compositions having circular RNAs encoding VEGF polypeptides. Related methods for manufacture and therapeutic uses thereof are also provided herein.
Resumen de: WO2025049816A1
A method for inserting a polynucleotide exogenous transgene sequence at a pre- determined endogenous genetic locus in a hose cell genome includes: (i) a donor DNA template including a polynucleotide insert; a 5 '-homology arm; and a 3 '-homology arm. In some embodiments, the 5' homology arm and the 3' homology arm are complementary to the DNA in a target region; and (ii) a ribonucleoprotein complex (RNP) including (1) a Cas nuclease, and at least one small guide RNAs (sgRNA) that is complementary to at least one selected nucleic acid sequence within the pre-determined genetic locus in the host cell genome.
Resumen de: CN121737164A
本发明公开了一种环状RNA及其在鸽毛滴虫疫苗中的应用。该环状RNA包含的编码元件能够编码重组鸽毛滴虫AP33或AP65蛋白。该编码元件具有SEQ ID NO.1或SEQ ID NO.2所示序列或其保守变异型序列。该环状RNA在动物体内可以诱导蛋白表达、产生高水平的抗体，其在应用为鸽毛滴虫疫苗时，不含感染性虫种成分，可在体内降解为核苷酸，不会整合到宿主基因组中，对鸽使用没有风险，并可刺激鸽产生较强的免疫反应，包括体液免疫和细胞免疫，从而有效抵御寄生虫感染，同时疫苗稳定性高，且本发明的疫苗可以通过分子技术大规模制备，生产成本低。
Resumen de: CN121732794A
本发明涉及一种高分散的超顺磁性金磁球形纳米粒子及其制备方法和应用，包括以下步骤：（a）在Fe3O4磁性微球表面包裹上mSiO2壳层得Fe3O4@ mSiO2磁性微球；（b）采用氨基硅烷对所述Fe3O4@ mSiO2磁性微球进行表面修饰；（c）将步骤（b）的产物与过量的金种溶液进行混合，得到Fe3O4@ mSiO2‑Au磁性微球；（d）将所述Fe3O4@ mSiO2‑Au磁性微球于金生长液中进行壳层的生长得到超顺磁性金磁球形纳米粒子。能够获得分散性好、包裹均匀的金磁球形纳米粒子，在不影响纳米粒子磁性的情况下，具有良好的拉曼增强效果。
Resumen de: CN121731454A
本申请涉及医药技术领域，具体公开了一种治疗关节炎的药物制剂及其制备方法，药物制剂由以下原料制成：雷公藤甲素1‑5重量份、芹菜素苹果酸酯20‑50重量份、三七总皂苷5‑15重量份、甘草酸5‑15重量份和药用多肽0.1‑10重量份。本申请以雷公藤甲素为核心攻击单元，通过引入甘草酸实现主动减毒；加入经苹果酸酯化修饰的芹菜素，在保留其多靶点抗炎活性的同时，彻底解决其生物利用度难题；辅以三七总皂苷改善微循环；并引入药用多肽，对炎症和骨破坏通路进行精准干预。
Resumen de: WO2025049579A1
The invention provides intranasal formulation for pulmonary delivery of nanoparticles, compositions, uses, and manufacturing methods thereof. In one aspect, an intranasal formulation for intranasal or intrapulmonary administration includes a viscosity agent, an epithelial adherence agent, and a foaming agent. The viscosity agent may include carboxymethylcellulose, the epithelial adherence agent may include poly-lysine, and the foaming agent may include gelatin hydrolysate.
Resumen de: CN121731241A
本发明提供了一种脂质纳米颗粒及其应用，具体地提供了一种基于甾醇化可电离脂质的无胆固醇LNP递送系统。该体系通过分子设计将甾醇基团作为疏水尾部整合至可电离脂质骨架中，形成新型甾醇化可电离脂质，并与辅助脂质、PEG‑脂质自组装形成稳定的三组分LNP。本发明克服了传统四组分LNP依赖胆固醇所导致的肝脏高富集问题，核心脂质显著降低了与载脂蛋白E的亲和力，有效规避ApoE/LDLR介导的肝细胞摄取途径。该LNP在完全无需胆固醇的条件下，同时实现了对mRNA的高包封率和优异稳定性，不仅大幅降低肝脏富集，还提高了对脾脏等肝外组织的靶向性，兼具高转染效率和良好生物相容性，为肝外疾病RNA药物的递送提供了创新平台。
Resumen de: AU2024288333A1
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by any of the formulae disclosed herein. The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations and pharmaceutical formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.
Resumen de: CN121737166A
本发明适用于生物医药技术领域，提供了用于预防或治疗乙肝病毒感染的单抗原或多抗原mRNA疫苗及其应用。mRNA编码的蛋白包括乙肝病毒表面抗原和/或乙肝病毒前表面抗原1融合泛HLA‑DR结合表位和人源IgG1 Fc段的融合蛋白（Pan‑HLA‑DR‑epitope‑preS1‑Fc）。将mRNA经过脂质纳米颗粒包裹为递送系统后，制备成单抗原或多抗原mRNA疫苗。该mRNA疫苗制剂能特异性增强针对乙肝病毒表面抗原和/或乙肝病毒前表面抗原1的体液免疫应答和细胞免疫应答，可用于乙型肝炎的预防和治疗；且mRNA疫苗制剂中各成分均可广泛获取，有效降低了疫苗成本、提高疫苗产量，具有良好的实际应用价值。
Resumen de: WO2026064791A1
Described herein are multivalent nanoparticles. In some embodiments, the multivalent nanoparticles contain a programmable stochiometric amount of three or more polypeptides attached to a lipid shell of the multivalent nanoparticles. In some embodiments, one or more of the polypeptides is an antigenic polypeptide. Also described herein are formulations, such as vaccine formulations, that can contain a multivalent nanoparticle described herein. Also described herein are methods of using the multivalent nanoparticles described herein, such as in a vaccine or drug delivery.
Resumen de: WO2026064744A1
The subject invention provides materials and methods for treating diseases affecting the central nervous system (CNS) and/or other viral reservoir organs utilizing nanoscopic diamond particles, i.e., nanodiamonds (ND), loaded with drug molecules and microglial targeting moiety.
Resumen de: WO2026063749A1
The present invention relates to a novel synthesis method for iodine-based nanoparticles and, more specifically, to iodine-based nanoparticles manufactured by electron beam irradiation, a method for manufacturing same, and a medical use thereof. Unlike conventional chemical synthesis methods, the method for manufacturing iodine-based nanoparticles, according to the present invention, can rapidly mass-produce small- and uniform-sized nanoparticles with a simple synthesis method using electron beam irradiation, and the iodine-based nanoparticles manufactured thereby are loaded with melittin and conjugated with transferrin, and thus can be used as a contrast agent for diagnostic imaging, as a drug delivery platform targeting a transferrin receptor, and as a therapeutic agent capable of treating vascular diseases by delivering drugs such as melittin.
Resumen de: WO2026063696A1
The present invention relates to a method for preparing a genetic material delivery nanogel, which is based on a positively charged polymer-naturally derived polymer-phenol compound copolymer, the method comprising the steps of: (1) introducing a carboxylic acid or amine group-containing phenol compound into a naturally derived polymer so as to prepare a naturally derived polymer-phenol compound copolymer, which is amide-bonded and cross-linkable; and (2) introducing a positively charged polymer or material into the naturally derived polymer-phenol compound copolymer of step (1) so as to prepare a positively charged polymer-naturally derived polymer-phenol compound copolymer, which is amide-bonded.
Resumen de: US20260083681A1
A formulation is provided for a spray dried lipid nanoparticle matrix particles, including lipid nanoparticles, a buffer system, and a barrier matrix stabilizer, wherein the barrier matrix stabilizer is included in a solid weight percent based on a maximum osmolarity and a maximum acceptable injectable volume of an injectable formulation comprising the spray dried lipid nanoparticle matrix particles.
Resumen de: US20260085081A1
A phosphatidylamine compound including a plurality of tertiary amino group structures and the composition thereof are provided. The phosphatidylamine compound is a phospholipid compound including two or more tertiary amino group structures, the structure of which is represented by the following formula (I). The compound works together with other lipid components such as cholesterol, DSPC/DOPE, DMG-PEG2000, and other helper lipids to form lipid nanoparticles (LNPs), which may be used for efficient delivery of drug molecules such as nucleic acids (siRNA, mRNA, pDNA), thereby realizing diagnosis and treatment of diseases such as cancer, fibrosis (e.g., liver, lung, kidney).
Resumen de: US20260083835A1
A non-infections bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.
Resumen de: US20260083830A1
The disclosure relates to microparticles and nanoparticles comprising a polymer matrix comprising an uncapped polymer and a net positively charged therapeutic agent at neutral pH. More particularly the disclosure relates to PLGA and/or PLA particles comprising an uncapped polymer for extended, controlled release of positively charged proteins or peptides at neutral pH. Methods of making the particles and administering the particles are also provided.
Resumen de: US20260083860A1
Disclosed are methods and compositions for functional genetic modifications at selected sites. Also provided are cell populations, which comprise targeted integration of one or more exogenous polynucleotides, and/or indels at one or more selected gene loci.
Nº publicación: US20260083770A1 26/03/2026
Solicitante:
OHIO STATE INNOVATION FOUND [US]
OHIO STATE INNOVATION FOUNDATION
Resumen de: US20260083770A1
Disclosed herein are compositions and methods for one step CMC production of RNA therapeutic complexes (nanostructures) that contain nucleoside analogues. In some embodiments, the nucleoside analogues are incorporated into RNA oligonucleotides that self-assemble into an RNA complex during RNA synthesis in a one-step production. Therefore, no additional conjugation or synthesis processes are required.
BOPI
Sede Electrónica
